Page last updated: 2024-10-30

leflunomide and Vitiligo

leflunomide has been researched along with Vitiligo in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Vitiligo: A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Awad, SS1

Other Studies

1 other study available for leflunomide and Vitiligo

ArticleYear
Leflunomide is a possible deactivator for vitiligo, a pilot study.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2012, Volume: 26, Issue:9

    Topics: Adult; Female; Humans; Isoxazoles; Leflunomide; Male; Pilot Projects; Vitiligo

2012